How ABILIFY ASIMTUFII® (aripiprazole) or ABILIFY MAINTENA® (aripiprazole) may help
ABILIFY ASIMTUFII and ABILIFY MAINTENA
each contain the same active medicine as oral ABILIFY tablets: aripiprazole.
Oral aripiprazole has been used to treat over 2 million people with bipolar disorders.* ABILIFY ASIMTUFII and ABILIFY MAINTENA are indicated for one type of bipolar disorder: bipolar I disorder.
*Based on the number of people who have received brand name or generic oral aripiprazole for bipolar disorders since 2015.
Shown to give more time between mood episodes
- A 1-year study measured how well symptoms were controlled in 266 people with bipolar I disorder. Half the people received ABILIFY MAINTENA and the other half received placebo†
- The study measured the time between mood episodes for adults living with bipolar I disorder
- The study found that those who were treated with ABILIFY MAINTENA remained mood episode-free significantly longer than those who were not treated with ABILIFY MAINTENA
Individual results may vary.
†A substance that contains no medicine.
In this study, significantly fewer people had a mood episode return while on ABILIFY MAINTENA (27%) compared with those who were on placebo (51%).
ABILIFY ASIMTUFII was approved based on key studies of ABILIFY MAINTENA
One of these was the 1-year study of ABILIFY MAINTENA shown above.
- Another key study was an 8-month study of ABILIFY ASIMTUFII and ABILIFY MAINTENA in 81 people with bipolar I disorder and 185 people with schizophrenia
- This study measured the levels of medicine (aripiprazole) in the body after 28 days of treatment with ABILIFY MAINTENA and 56 days of treatment with ABILIFY ASIMTUFII
- The results showed that the medicine in ABILIFY ASIMTUFII stayed at a similar level in the body for 2 months as the medicine in ABILIFY MAINTENA did for 1 month
The safety of ABILIFY ASIMTUFII is based on established studies of ABILIFY MAINTENA. See more information on safety and side effects.
Watch Emma’s story about choosing ABILIFY ASIMTUFII
Emma’s story about choosing ABILIFY ASIMTUFII
Emma: My bipolar I disorder symptoms were so unpredictable, committing to things could be hard. But with more time between mood episodes, I feel like I can look ahead. And I want to make that last.
So I talked to my doctor about starting on ABILIFY ASIMTUFII.
Announcer: ABILIFY ASIMTUFII, an injection given by a healthcare provider, is the first FDA-approved once every-2-months maintenance treatment for bipolar I disorder in adults. Just one dose every 2 months may provide long-lasting symptom control.
ABILIFY ASIMTUFII can cause serious side effects.
Elderly dementia patients have increased risk of death or stroke. Call your doctor about fever, stiff muscles, and confusion, which could be life-threatening; or uncontrolled body movements, which may not go away. Risks include potentially fatal high blood sugar, high cholesterol, weight gain, low white blood cells, unusual urges, dizziness on standing, seizures, injection site pain, and trouble swallowing.
Emma: With ABILIFY ASIMTUFII, I’m looking forward to what’s ahead.
Announcer: For long-lasting symptom control…
Singing: ABILIFY ASIMTUFII
©2025 Otsuka America Pharmaceutical, Inc. All rights reserved.
July 2025 23US25EBC0042
Create your Doctor Discussion Guide
What are the side effects of these long-acting injectables (LAIs)?